Safety and Efficacy of Telehealth Medication Abortions in the US During the COVID-19 Pandemic
Open Access
- 24 August 2021
- journal article
- letter
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 4 (8) , e2122320
Abstract
Early in the COVID-19 pandemic, medication abortion, which typically includes mifepristone (ie, progesterone receptor antagonist) and misoprostol (ie, prostaglandin), gained prominence because it can be provided without physical contact. The American College of Obstetricians and Gynecologists and other professional organizations quickly endorsed telehealth and no-test abortion care.1 These protocols omit Rh testing2 and use patient history, rather than routine ultrasonography, to assess pregnancy duration and screen for ectopic pregnancy risks.3,4Keywords
This publication has 5 references indexed in Scilit:
- Effectiveness, safety and acceptability of no‐test medical abortion (termination of pregnancy) provided via telemedicine: a national cohort studyBJOG: An International Journal of Obstetrics & Gynaecology, 2021
- Commentary: No-test medication abortion: A sample protocol for increasing access during a pandemic and beyondContraception, 2020
- Foregoing Rh testing and anti-D immunoglobulin for women presenting for early abortion: a recommendation from the National Abortion Federation's Clinical Policies CommitteeContraception, 2019
- Simplified medical abortion screening: a demonstration projectContraception, 2018
- Incidence of Emergency Department Visits and Complications After AbortionObstetrics & Gynecology, 2015